Companies in Genomics
There are 9,234 companies in Genomics which include Ancestry, Alnylam, Guardant Health, Natera, GRAIL. 3,816 companies in Genomics are funded, with 1,902 having secured Series A funding. Till date, the sector has seen the creation of 20 Unicorns. United States has the most number of companies in Genomics (4,058), followed by United Kingdom
(583), and then China (567).
2026 has seen the creation of 86 Genomics companies. On average, the last 10 years have seen 272 new companies launched every year. Most number of Genomics startups have been founded by alumni from Stanford University, Harvard University and Massachusetts Institute of Technology.
Here is a List of top companies in Genomics
1. Ancestry
Ancestry is a provider of an online genealogy platform offering a host of services. It offers family history information, historical records, and other genealogical information. It enables users to create their family tree and helps them discover, preserve and share their family history. The company uses microarray-based autosomal DNA testing technology and an online family history resource to predict family connections and relatives. The company offers a subscription-based service. The company claims its online resource contains all relevant Federal Census records since 1790 (Archives).
Key facts about Ancestry
- Founded Year: 1996
- Location: Lehi (United States)
- Stage: Acquired
- Total Funding till date: $446M
- Investors: AOL, Signal Peak and 19 Others
- Latest Funding Round: Post IPO, Apr 2016, $*****
- Tracxn Score: 85/100 What is this?
- Competitors Rank: 1 of 142 Competitors
2. Alnylam
Developer of RNA interference-based therapeutics for multiple disorders. Its pipeline includes drugs that are used to treat hereditary ATTR Amyloidosis, acute hepatic porphyria, and treating hypercholesterolemia. It also develops drugs for cardiometabolic diseases, infectious diseases, central nervous system, and ocular diseases.
Key facts about Alnylam
- Founded Year: 2002
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $17M
- Investors: Military Health, GUB and 14 Others
- Latest Funding Round: Post IPO, Aug 17, 2020, $*****
- Tracxn Score: 81/100 What is this?
- Competitors Rank: 2 of 1,046 Competitors
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Key facts about Guardant Health
- Founded Year: 2012
- Location: Redwood City (United States)
- Stage: Public
- Total Funding till date: $557M
- Investors: Sequoia Capital, SoftBank Vision Fund and 25 Others
- Latest Funding Round: Post IPO, Nov 05, 2025, $*****
- Tracxn Score: 80/100 What is this?
- Competitors Rank: 1 of 687 Competitors
4. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Stage: Public
- Total Funding till date: $152M
- Investors: Sequoia Capital, HRC Fertility and 18 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Tracxn Score: 79/100 What is this?
- Competitors Rank: 2 of 846 Competitors
5. GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Key facts about GRAIL
- Founded Year: 2016
- Location: Menlo Park (United States)
- Stage: Public
- Total Funding till date: $2B
- Investors: Arch Venture Partners, CPP Investments and 52 Others
- Latest Funding Round: Post IPO, Jun 25, 2026, $*****
- Tracxn Score: 79/100 What is this?
- Competitors Rank: 2 of 352 Competitors
